

Inventor(s): Flannery et al.

Appln. No.: 09 463,844

Series Code ↑ Serial No. ↑

Filed: February 1, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1632

Examiner: Schnizer, R.

Atty. Dkt. P 0265461 PHM 70251/UST

M# Client Ref

Appln. Title: ZGGBP1. Novel Peptides Related to
Bipolar Affective Disorders Type 1,
Sequences and Uses Thereof

Sir:

REPLY/AMENDMENT/LETTER

Date: September 7, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

A ☒ NOT madeB ☐ WithdrawnC ☐ made herewithD ☐ made previouslyFor B & C
See **Required**
Separate Paper
(Pat-256)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	40	**minus 40	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	6	***minus 6	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: June 8, 2000	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo)	\$110/\$55 =				115/215
	(2 mos)	\$390/\$195 =		+ \$1890		116/216
	(3 mos)	\$890/\$445 =				117/217
	(Usable only for ≤ 2mo.OA --- 4 mos)	\$1390/\$695=				118/218
	(Usable only for 30 day/1mo.OA --- 5 mos)	\$1890/\$945=				128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0		
8. Extension Fee Attached				+ \$1890		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),				+ \$180	+ \$0	126
or if Rule 97(d) Request				+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....				x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)				+ \$710/355	+ \$0	1179/1279
14. Petition fee for					+ \$0	
15. TOTAL FEE ENCLOSED =					\$1890	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 009901 0265461

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP

Intellectual Property Group

1600 Tysons Boulevard

By Atty: Donald J. Bird

Reg. No. 25323

McLean, VA 22102

Sig:

Fax: (703) 905-2500

Tel: (703) 905-2000

Tel: (703) 905-2018

Atty/Sec: DJB/AMX

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

1632/118 L
9-12-0
Box Seq \$P.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION of

Group Art Unit: 1632

FLANNERY et al.

Examiner: Schnizer, R.

Appln. No.: 09/463,844



Filed: February 1, 2000

FOR: ZGGBP1, Novel Peptides Related to Bipolar Affective Disorders Type 1, Sequences and Uses Thereof


Date: September 8, 2001

Submission Under 37 CFR §§ 1.821 Et Seq.,

and

Amendment to Comply With Sequence Listing Rules

DISK TO STIC



DATE:

Assistant Commissioner for Patents

Washington, D.C. 20231

09/10/2001 TGEDAMU1 00000073 09463844

01 FC:128 Sir: 1890.00 DP

In response to the Notification to Comply with Requirements dated June 8, 2001, Applicants submit the following amendments to comply with Sequence Listing Rules.

Amendments

Please delete the Sequence Listing originally filed with the application that appears on pages 1-16 of the application. In its place, please enter the enclosed Sequence Listing on separate pages after the claims and abstract of the application.

On page 7 of the specification, please amend lines 29-31 to read as follows:

Figure 1 shows the predicted amino acid sequence (SEQ ID NO:2) of ZGGBP1. The C2 domain is indicated by carets, the four WW domains are indicated by asterisks and the Hect domain is indicated by underlining.

B1
Sub 26

Figure 2 shows a comparison of amino acid sequences of human ned4 Swissprot entry P46934 (SEQ ID NO:6) and ZGGBP1 (SEQ ID NO:2). Figure 3 shows a Northern blot analysis of various human tissues probed with ZGGBP1.

Figure 4 shows a comparison of the nucleic acid sequences of human (SEQ ID NO:7) and mouse (SEQ ID NO:3) ZGGBP1. The mouse sequence is a partial cDNA which spans the C-terminal portion of the human protein coding region.

Figure 5 shows a comparison of the nucleic acid sequences for ZGGBP1 (SEQ ID NO:1) and Pub3 (SEQ ID NO:8).

Figure 6 shows a polymorphism located at position 3554 of the cDNA sequence (SEQ ID NO:10) (SEQ ID NO:11).

Figure 7 shows a polymorphism located at position 4828 of the cDNA sequence (SEQ ID NO:12) (SEQ ID NO:13).

Figure 8 shows a polymorphism located in an intronic sequence (SEQ ID NO:14) (SEQ ID NO:15) derived from a BAC containing ZGGBP1.

Figure 9 shows a variable number of tetranucleotide repeats located within an intronic sequence (SEQ ID NO:9) from ZGGBP1.

Figure 10 shows an insertion at position 4032 of the cDNA sequence (SEQ ID NO:16) (SEQ ID NO:17).